Pamiparib

Drug Overview

Pamiparib (marketed under the brand name Partruvix™) is an investigational, orally bioavailable, highly selective small-molecule inhibitor of poly(ADP-ribose) polymerase 1 and 2 (PARP1/2). It is a potent antineoplastic agent specifically engineered to exploit the “synthetic lethality” in cancer cells with DNA repair deficiencies.

In the clinical landscape of March 2026, pamiparib is recognized for its unique pharmacological profile, particularly its ability to cross the blood-brain barrier (BBB). Unlike many earlier PARP inhibitors (such as olaparib or niraparib), pamiparib is not a substrate for P-glycoprotein (P-gp), a pump that typically ejects drugs from the central nervous system. This makes it a high-potential candidate for treating primary brain tumors and brain metastases. Additionally, pamiparib demonstrates powerful PARP-DNA trapping—a process where the drug “locks” the PARP enzyme onto damaged DNA, creating a physical roadblock that leads to cell death during replication. Developed by BeiGene, pamiparib received its first regulatory approval in China in 2021 and is currently being evaluated in global Phase 2 and Phase 3 trials for advanced ovarian, gastric, and breast cancers.

• Generic Name: Pamiparib.
• Brand Name: Partruvix™ (Approved in China).
• Code Name: BGB-290.
• Drug Class: PARP1/2 Inhibitor; Targeted Therapy.
• Mechanism: Selective inhibition of PARP1/2 enzymes and potent trapping of PARP-DNA complexes, leading to double-strand DNA breaks and apoptosis.
• Route of Administration: Oral (Capsule).
• FDA Approval Status: Investigational. As of March 2026, pamiparib is not FDA-approved in the United States. It is approved in China for recurrent ovarian, fallopian tube, or primary peritoneal cancer with germline BRCA mutations.

What Is It and How Does It Work? (Mechanism of Action)

Pamiparib works by “sabotaging” the repair machinery that cancer cells use to survive daily genetic damage.

1. Inhibition of Single-Strand Break (SSB) Repair

Every day, cells experience thousands of single-strand breaks in their DNA. The PARP enzyme is the “first responder” that detects these breaks and recruits repair proteins.

• The Blockade: Pamiparib binds to the active site of PARP1 and PARP2, preventing them from repairing these nicks.
• Accumulation of Damage: Unrepaired SSBs are converted into more dangerous double-strand breaks (DSBs) during the S-phase of the cell cycle (DNA replication).

2. Synthetic Lethality (BRCA and HRD)

In healthy cells, DSBs are repaired by a process called Homologous Recombination (HR), which involves the BRCA1 and BRCA2 proteins.

• The “Two-Hit” Model: In cancer cells with a BRCA mutation or Homologous Recombination Deficiency (HRD), this backup repair system is broken.
• Cellular Death: When pamiparib blocks the primary repair (PARP) in a cell that already lacks the backup repair (HRD), the cell accumulates lethal levels of DNA damage and dies. This “synthetic lethality” allows the drug to kill cancer cells while sparing healthy ones.

3. Potent PARP-DNA Trapping

[Image: Illustration of pamiparib trapping PARP enzymes on a DNA strand]

Beyond simple inhibition, pamiparib acts like a “molecular glue.” It traps the PARP enzyme on the DNA at the site of the break. This trapped complex is significantly more toxic than the DNA break alone because it collapses the entire replication machinery as the cell tries to divide.

Clinical Indications and Research Status (2026)

In 2026, the clinical development of pamiparib is focused on expanding its use into “unmet” areas of oncology:

• Recurrent Ovarian Cancer (gBRCAm): This is the most mature area of research. In Phase 2 trials, pamiparib demonstrated an Objective Response Rate (ORR) of approximately 64.6% in patients with germline BRCA mutations who had received at least two prior lines of chemotherapy.
• Advanced Gastric Cancer: The Phase 3 PARALLEL 303 trial (NCT03427814) evaluated pamiparib as maintenance therapy after platinum-based chemotherapy. While the trial showed a longer median progression-free survival for pamiparib (3.7 months vs 2.1 months), it did not reach statistical significance, leading to ongoing 2026 studies into more specific “HRD-positive” gastric cancer subsets.
• HER2-Negative Breast Cancer: Investigated as a monotherapy for patients with BRCA mutations. Recent data show ORRs of 38% in triple-negative and 62% in hormone receptor-positive metastatic cohorts.
• Glioblastoma and Brain Metastases: Due to its superior BBB penetration, pamiparib is being combined with temozolomide (TMZ) and radiation to treat aggressive brain tumors.
• Neoadjuvant Therapy: In early 2026, results from the PASSION trial showed that combining pamiparib with the VEGFR inhibitor surufatinib before surgery could achieve a complete resection (R0) in over 92% of patients with unresectable ovarian cancer.

Dosage and Administration Protocols

As an investigational agent in most regions, dosing is meticulously monitored to manage potential hematologic effects.

Safety Profile and Side Effects

The side effects of pamiparib are consistent with the “PARP inhibitor class,” with a specific focus on blood counts.

1. Hematologic Toxicity (Most Significant)

• Anemia: Occurs in roughly 100% of patients to some degree; Grade 3 or higher anemia is seen in ~38%.
• Neutropenia and Leukopenia: A drop in white blood cells increases the risk of infection.
• Thrombocytopenia: A drop in platelets (seen in ~77% of patients) increases the risk of bleeding.
• Management: Regular blood tests are mandatory; dose reductions or “treatment holidays” are used to allow bone marrow recovery.

2. Gastrointestinal Effects

• Nausea/Vomiting: Common during the first few weeks of treatment; usually manageable with anti-emetics.
• Loss of Appetite: Can impact nutritional status, requiring dietary counseling.

3. General Side Effects

• Fatigue: Reported by most patients; can range from mild tiredness to severe lack of energy.
• Liver Enzymes: Elevated ALT/AST levels may occur, requiring periodic liver function tests.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, pamiparib is used to study “Genomic Stability.” Researchers are investigating if transient PARP inhibition can be used to “prime” Hematopoietic Stem Cells before gene editing. In 2026, there is also intense focus on “Immune-Oncology Combinations.” Scientists are pairing pamiparib with tislelizumab (a PD-1 inhibitor) to see if the “DNA damage” caused by the PARP inhibitor can attract more immune cells into the tumor, turning “cold” tumors into “hot” ones.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• BRCA/HRD Testing: Mandatory genetic testing to ensure the tumor has the molecular “vulnerability” needed for the drug to work.
• Baseline Blood Count: To ensure bone marrow function is sufficient before starting therapy.

“Do’s and Don’ts” List:

• DO report any “unusual shortness of breath” or “extreme dizziness,” as these are early signs of severe anemia.
• DO maintain strict adherence to your BID schedule; the drug’s effectiveness depends on continuous PARP trapping.
• DON’T take St. John’s Wort or eat grapefruit, as these can significantly change how much drug stays in your blood.
• DON’T ignore a fever over 100.4°F, which could be a sign of a dangerously low white blood cell count (neutropenia).

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Pamiparib (Partruvix) is an investigational agent and is not approved by the U.S. FDA for commercial use. Access is restricted exclusively to registered clinical trials. Always consult with a board-certified oncologist regarding your specific diagnosis, BRCA status, and eligibility for active PARP inhibitor research.